Rdif, Company

Lasa Supergenerics Limited (BSE: 540702, NSE: LASA), pioneer and amongst the leading players in the manufacturing of Veterinary and Human APIs in India through its catalyst chemistry expertise and fully backward integrated unit, has added another product - Oxyclozanide to its portfolio of products.Oxyclozanide is an anthelmintic, it is used in the treatment and control of fascioliasis a topical worm infection in ruminants mainly domestic animals such as cattle (especially buffalos in farm), sheep, and goats. For this, the Company is setting up capacity in a brown field expansion at its Chiplun unit. The total capacity would be 20 MT and would be funded through internal accruals. The Company is committed to funding the entire capex through internal accruals. The production would start from August 2021.The product is in huge demand and the management is confident of having a strong order book from the time production commences. The Company already has export approvals for several regions. Oxyclozanide would also be exported to these regions.Commenting on the recent development, Dr. Omkar Herlekar, Chairman & Managing Director, Lasa Supergenerics Limited said, "We are very pleased to inform that the Company has added another interesting product to its portfolio. Oxyclozanide is an anthelmintic. It has a huge opportunity both in domestic as well export markets. The additional capacity is being put within the existing facility at Chiplun, Maharashtra. This, like other products, is also a difficult product to manufacture and hence there are not many players manufacturing it. Also, it is a product of regular consumption within the veterinary space. Since we already possess various certificates to export to different regions, we would be targeting both domestic and export markets. We are very excited about the launch of Oxyclozanide as it fit our product selection criteria and we are confident of grabbing a significant market share. The Company is in a phase of evolution and growth and we will strive hard and deliver on the expected lines.""I would like to thank the entire team of 'LASA' for their untiring efforts, hard work, sincerity and high dedication. Also, I would like to thank our valued Shareholders, whose support and faith in our Company has given us the determination and ambition to go from strength to strength."Lasa Supergenerics Limited is a globally well trusted brand with high quality products, accepted by large companies across the globe. The Company is a pioneer and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. It specializes in 'catalyst chemistry' and manufactures anthelmintic/veterinary API. To efficiently control the supply chain, the company has backward integrated its key molecules. The Company has its unit with state of art manufacturing facilities located at Mahad & Chiplun, Maharashtra. The Company exports APIs to counties like Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea, Pakistan etc.For more details, please visit, .This story is provided by NewsVoir.will not be responsible in any way for the content of this article. (ANI/NewsVoir)( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

RdifFOLLOW

Rdif, Latest News

Moscow, July 7 Pharma major Morepen Laboratories has started the production of the test batch of the Russian ... ...

Russian Direct Investment Fund (RDIF) and Indian drug firm Morepen Laboratories on Tuesday announced the production of the test batch of the Russian Sputnik V coronavirus vaccine in an exclusive facility in Himachal Pradesh. ...

Mexico has produced the first test batch of the Russian Sputnik V COVID-19 vaccine at a local plant, the Russian Direct Investment Fund (RDIF) said on Monday. ...

Prabhuji Online, India's fastest growing technology enabled "Subscription Commerce Company", has raised an undisclosed amount of funds in pre-series A round from Singapore and India based marquee angel investors. ...

The Russian Direct Investment Fund (RDIF) on Tuesday announced that the efficacy of the Russian COVID-19 vaccine Sputnik V in the United Arab Emirates (UAE) was confirmed at 97.8 per cent among over 81,000 subjects. ...

Iran's leading pharmaceutical companies, Actoverco has produced a test batch of Russian Sputnik V vaccine against coronavirus, the Russian Direct Investment Fund (RDIF) announced on Saturday. ...

Godfrey Phillips India bags the coveted title of Best Companies to Work For 2021. Participating for the third year, Godfrey Phillips India received a ranking of 28th this year. ...

Lasa Supergenerics Limited (BSE: 540702, NSE: LASA), pioneer and amongst the leading players in the manufacturing of Veterinary and Human APIs in India through its catalyst chemistry expertise and fully backward integrated unit, has added another pro ...